SEC Form 4 · accession 0001193125-26-392025
Artiva Biotherapeutics, Inc. · ARTV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fred Aslan
Officer — Chief Executive Officer · Director
Period of report
Sep 15, 2026
Accepted (ET)
Sep 15, 2026 · 4:44 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001817241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 15, 2026 | A | 110,000 | $0.00 | A | 1,604,765 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $8.91 | Sep 15, 2026 | A | 315,000 | A | — | Sep 14, 2036 | Common Stock | 315,000 | 315,000 | D |
Explanation of responses
- F1Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
- F2Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period.